ImmunoPrecise Antibodies Ltd. recently held their Fourth Quarter and Fiscal Year End 2025 Earnings Call, as documented in their published transcript. The call was led by CEO Dr. Jennifer Lynne Bath and Interim CFO Joseph Scheffler, with participation from analyst Swayampakula Ramakanth of H.C. Wainwright & Co, LLC. During the call, Dr. Bath highlighted a record-setting fourth quarter for the company, with revenue reaching $7 million, marking the highest quarterly revenue in the company's history. She also noted the improvement in gross margin to 64% from 48% in the same quarter of the previous fiscal year, attributed to "operational efficiency and disciplined execution." For the full fiscal year ending April 30, 2025, the company expanded its gross margins by 600 basis points, from 49% to 55%, driven by the substantial growth of the BioStrand segment, which grew over 180% year-over-year and achieved gross margins nearing 90%. Dr. Bath emphasized the company's focus on continuous improvement and strategic initiatives: "Fiscal year 2025 was a standout year for Precise Antibodies." The full transcript can be accessed through the link below.